Cargando…
Vitiligoid hypopigmentation associated with pembrolizumab in metastatic head and neck cancer
Cutaneous adverse events are common with the use of immunotherapy. Although only 5% of patients develop severe reactions, about half will develop mild to moderate cutaneous adverse events. Vitiligo has been seen in melanomas treated with checkpoint inhibitors (CPI). We describe the first known case...
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Oxford University Press
2019
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6440267/ https://www.ncbi.nlm.nih.gov/pubmed/30949354 http://dx.doi.org/10.1093/omcr/omz016 |